Literature DB >> 33767705

The Local and Systemic Humoral Immune Response Against Homologous and Heterologous Strains of the Type 2 Porcine Reproductive and Respiratory Syndrome Virus.

Andrew R Kick1, Amanda F Amaral1, Alba Frias-De-Diego1, Lizette M Cortes1, Jonathan E Fogle1, Elisa Crisci1, Glen W Almond1, Tobias Käser1.   

Abstract

The humoral immune response plays a crucial role in the combat and protection against many pathogens including the economically most important, highly prevalent, and diverse pig pathogen PRRSV - the Porcine Reproductive and Respiratory Syndrome Virus. In addition to viremia and viral shedding analyses, this study followed the local and systemic humoral immune response of pigs for 63 days upon inoculation with one of three types of Type-2 PRRSV (PRRSV-2) strains - one modified live virus (MLV) vaccine strain, and two lineage 1 PRRSV-2 strains, NC134 and NC174. The local response was analyzed by quantifying immunoglobulin (Ig)A in nasal swabs. The systemic response was studied by the quantification of IgG with ELISA and homo- and heterologous neutralizing antibodies (NAs) utilizing a novel method of flow cytometry. In all PRRSV-2 inoculated groups, viral nasal shedding started at 3 dpi, peaked between 3 and 7 days post inoculation, and was cleared at 28-35 dpi with sporadic rebounds thereafter. The local IgA response started 4-7 days after viral shedding occurred and showed a bi-phasic course with peaks at 14 dpi and at 28-35 dpi. Of note, the NC134 and NC174 strains induced a much stronger local IgA response. As reported earlier, main viremia lasted from 7 dpi to 28 dpi (NC174), 42 dpi (NC134) or until the end of the study (MLV). Similar to the local IgA response, the systemic IgG response started 4-7 days after viremia; but in contrast to viremia, serum IgG levels stayed high for all PRRSV-2 inoculated groups until the end of the study. A significant finding was that while the serum NA response in the MLV group was delayed by 28 days, serum NAs in pigs infected with our two NC134 and NC174 strains could be detected as early as 7 dpi (NC134) and 14 dpi (NC174). Compared to homologous NA responses, the NA responses against heterologous strains was strong but slightly delayed between our lineage 1 one strains or non-existent between the MLV and lineage 1 strains. This study improves our understanding of the relationship between local and systemic infections and the humoral immune response induced by PRRSV-2 infection or MLV vaccination. Our data also provide novel insights into the timeline of the development of homologous and heterologous NA levels - by both MLV vaccination or infection with two strains from the currently prevalent PRRSV-2 lineage 1.
Copyright © 2021 Kick, Amaral, Frias-De-Diego, Cortes, Fogle, Crisci, Almond and Käser.

Entities:  

Keywords:  IgA; IgG; adaptive immunity; humoral immunity; neutralizing antibodies; porcine reproductive and respiratory syndrome virus

Year:  2021        PMID: 33767705      PMCID: PMC7985350          DOI: 10.3389/fimmu.2021.637613

Source DB:  PubMed          Journal:  Front Immunol        ISSN: 1664-3224            Impact factor:   7.561


  42 in total

Review 1.  Role of neutralizing antibodies in PRRSV protective immunity.

Authors:  O J Lopez; F A Osorio
Journal:  Vet Immunol Immunopathol       Date:  2004-12-08       Impact factor: 2.046

2.  Cross reactivity of immune responses to porcine reproductive and respiratory syndrome virus infection.

Authors:  Ignacio Correas; Fernando A Osorio; David Steffen; Asit K Pattnaik; Hiep L X Vu
Journal:  Vaccine       Date:  2017-01-03       Impact factor: 3.641

Review 3.  Immunological solutions for treatment and prevention of porcine reproductive and respiratory syndrome (PRRS).

Authors:  Michael P Murtaugh; Marika Genzow
Journal:  Vaccine       Date:  2011-09-17       Impact factor: 3.641

4.  Mycoplasma hyopneumoniae potentiation of porcine reproductive and respiratory syndrome virus-induced pneumonia.

Authors:  E L Thacker; P G Halbur; R F Ross; R Thanawongnuwech; B J Thacker
Journal:  J Clin Microbiol       Date:  1999-03       Impact factor: 5.948

5.  Pathogenesis and antigenic characterization of a new East European subtype 3 porcine reproductive and respiratory syndrome virus isolate.

Authors:  Uladzimir U Karniychuk; Marc Geldhof; Merijn Vanhee; Jan Van Doorsselaere; Tamara A Saveleva; Hans J Nauwynck
Journal:  BMC Vet Res       Date:  2010-06-04       Impact factor: 2.741

6.  Characterization of homologous and heterologous adaptive immune responses in porcine reproductive and respiratory syndrome virus infection.

Authors:  Ivan Díaz; Mariona Gimeno; Laila Darwich; Nuria Navarro; Liudmila Kuzemtseva; Sergio López; Ivan Galindo; Joaquim Segalés; Margarita Martín; Joan Pujols; Enric Mateu
Journal:  Vet Res       Date:  2012-04-19       Impact factor: 3.683

7.  Vaccination of sows against type 2 Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) before artificial insemination protects against type 2 PRRSV challenge but does not protect against type 1 PRRSV challenge in late gestation.

Authors:  Kiwon Han; Hwi Won Seo; Changhoon Park; Chanhee Chae
Journal:  Vet Res       Date:  2014-02-02       Impact factor: 3.683

8.  Comparison of host immune responses to homologous and heterologous type II porcine reproductive and respiratory syndrome virus (PRRSV) challenge in vaccinated and unvaccinated pigs.

Authors:  X Li; A Galliher-Beckley; L Pappan; B Trible; M Kerrigan; A Beck; R Hesse; F Blecha; J C Nietfeld; R R Rowland; J Shi
Journal:  Biomed Res Int       Date:  2014-02-26       Impact factor: 3.411

9.  The T-Cell Response to Type 2 Porcine Reproductive and Respiratory Syndrome Virus (PRRSV).

Authors:  Andrew R Kick; Amanda F Amaral; Lizette M Cortes; Jonathan E Fogle; Elisa Crisci; Glen W Almond; Tobias Käser
Journal:  Viruses       Date:  2019-08-29       Impact factor: 5.048

10.  Dynamics and Differences in Systemic and Local Immune Responses After Vaccination With Inactivated and Live Commercial Vaccines and Subsequent Subclinical Infection With PRRS Virus.

Authors:  Miroslav Toman; Vladimir Celer; Lenka Kavanová; Lenka Levá; Jitka Frolichova; Petra Ondráčková; Hana Kudláčková; Kateřina Nechvátalová; Jiri Salat; Martin Faldyna
Journal:  Front Immunol       Date:  2019-08-06       Impact factor: 7.561

View more
  4 in total

1.  Systems Immunology Analyses Following Porcine Respiratory and Reproductive Syndrome Virus Infection and Vaccination.

Authors:  Loïc Vivien Bocard; Andrew Robert Kick; Corinne Hug; Heidi Erika Lisa Lischer; Tobias Käser; Artur Summerfield
Journal:  Front Immunol       Date:  2021-12-16       Impact factor: 7.561

2.  Simultaneous Infection With Porcine Reproductive and Respiratory Syndrome and Influenza Viruses Abrogates Clinical Protection Induced by Live Attenuated Porcine Reproductive and Respiratory Syndrome Vaccination.

Authors:  Tiphany Chrun; Emmanuel A Maze; Eleni Vatzia; Veronica Martini; Basudev Paudyal; Matthew D Edmans; Adam McNee; Tanuja Manjegowda; Francisco J Salguero; Nanchaya Wanasen; Surapong Koonpaew; Simon P Graham; Elma Tchilian
Journal:  Front Immunol       Date:  2021-11-11       Impact factor: 7.561

3.  Differences in Humoral Immune Response against the Type 2 Porcine Reproductive and Respiratory Syndrome Virus via Different Immune Pathways.

Authors:  Wen Li; Yangyang Sun; Shijie Zhao; Zhiying Cui; Yu Chen; Pengli Xu; Jing Chen; Yina Zhang; Pingan Xia
Journal:  Viruses       Date:  2022-06-29       Impact factor: 5.818

4.  Heterologous vaccine immunogenicity, efficacy, and immune correlates of protection of a modified-live virus porcine reproductive and respiratory syndrome virus vaccine.

Authors:  Jessica Proctor; Iman Wolf; David Brodsky; Lizette M Cortes; Alba Frias-De-Diego; Glen W Almond; Elisa Crisci; Tatiane Terumi Negrão Watanabe; James M Hammer; Tobias Käser
Journal:  Front Microbiol       Date:  2022-09-23       Impact factor: 6.064

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.